Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches
NCT06582810
Recruiting
The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage; 2. show that intravenous lidocaine infusion is safe in treating headache fol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Ascension Via Christi St. Francis, Wichita, Kansas
Conditions: Subarachnoid; Hemorrhage, Nontraumatic, Headache
Register for Updates
The Options 2 Study
NCT06595459
Recruiting
The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products. Participants will: * Use nicotine pouches, nicotine mini lozenges, or no study product for a week and then try not to smoke for 3 weeks. * Have 6 in-person research visits and 1 follow-up call * Complete questionnaires at each study contact and use a smartphone app to record... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/14/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Smoker, Smoking Cessation
Register for Updates
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106
Recruiting
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to elimina... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
07/14/2025
Locations: Collaborative Neuroscience Research, LLC, Los Alamitos, California +4 locations
Conditions: Healthy, Obesity
Register for Updates
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226
Recruiting
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/14/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +95 locations
Conditions: Sickle Cell Disease, Thalassemia
Register for Updates
Effects of E-cigarette Use on Health
NCT06610838
Recruiting
Electronic nicotine delivery systems (ENDS) are used by millions of Americans, however their long-term health effects are unknown. This research proposal will quantify the effects of long-term ENDS use on validated and novel biomarkers of cardiovascular and pulmonary disease and how they are influenced by use heaviness, age, body weight, and co-use of other products. This study will produce the most informative evidence to date on how long-term ENDS use affects cardiovascular and pulmonary healt... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/14/2025
Locations: UW Center for Tobacco Research and Intervention, Madison, Wisconsin
Conditions: Electronic Cigarette Use
Register for Updates
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/14/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +160 locations
Conditions: Sickle Cell Disease
Register for Updates
Accountability Support Through Peer-Inspired Relationships and Engagement (ASPIRE) Trial
NCT06617702
Recruiting
This project aims to test the efficacy of a text message intervention, ASPIRE, designed to address cognitive and behavioral elements and modify exposure to peers that influence drinking behaviors. Young adults who are contemplating reducing their drinking will be recruited from a national sample and randomized to ASPIRE versus a text message intervention focused solely on cognitive and behavioral elements. We will measure effectiveness at 3, 6, and 12 months, study mechanisms driving behavior ch... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
07/14/2025
Locations: Stanford University, Palo Alto, California
Conditions: Alcohol Consumption
Register for Updates
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06625190
Recruiting
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for hematologic malignancies and non-malignant diseases additionally increasing the donor pool as to allow for haploidentical transplant to safely occur. While solid tumors can be highly chemotherapy sensitive, many remain resistant and require multimodalities of treatment. Immun... Read More
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
07/14/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors, Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, Desmoplastic Small Round Cell Tumor, Chordoma, Rhabdoid Tumor, Epithelioid Sarcoma, Myoepithelial Tumor, Osteosarcoma, Ewing Sarcoma
Register for Updates
Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
NCT06670638
Recruiting
To date, patients with Crohn's Disease (CD) and permanent ileostomies have been excluded from clinical trials for new treatments. To allow this patient population to be included in clinical trials, outcome and measurement tools are needed. This study aims to develop a Patient Reported Outcome (PRO) and Endoscopic Index (EI) for patients with Crohn's Disease (CD) and permanent ileostomy. The study will enroll about 50 participants and collect videos of endoscopies that are done as part of standar... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Mayo Clinic- Rochester, Rochester, Minnesota +3 locations
Conditions: Crohns Disease
Register for Updates
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
NCT06675136
Recruiting
This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Register for Updates
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
NCT06698926
Recruiting
This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/14/2025
Locations: Acpru /Id# 270532, Grayslake, Illinois
Conditions: Healthy Volunteer
Register for Updates
StandUPTV Habits: Feasibility Trial for Maintaining Reductions in Sedentary Screen Time
NCT06700525
Recruiting
Our goal in this study is to further refine StandUPTV, an application designed to reduce SST in adults in our first study (ASU IRB # STUDY00012109), for the StandUPTV Habits program. This program aims to establish a non-sedentary habit triggered by an alert from the StandUPTV application after participants engage in approximately 30 minutes of SST in the evening.
Gender:
ALL
Ages:
Between 23 years and 64 years
Trial Updated:
07/14/2025
Locations: Arizona State University, Tempe, Arizona +1 locations
Conditions: Sedentary Behaviors, Screen Time, Physical Activity, Glucose Metabolism, Sleep Quality, HbA1c Level
Register for Updates